Patients with COVID-19 in the intensive care unit (ICU) prescribed full-dose blood thinners are significantly more likely to experience heavy bleeding than patients prescribed a smaller yet equally effective dose, according to a recent University at Buffalo-led study.
Despite opposition from The World Health Organization, officials in Spain are calling for governments to start dealing with COVID-19 as if it were any other endemic respiratory virus.
Preliminary studies early in the pandemic found evidence that countries with Bacillus Calmette-Guérin vaccination programs, which fights tuberculosis, could be associated with a reduced number of COVID-19 cases.
The CDC says people with COVID-19 should isolate for 5 days and if they are asymptomatic or their symptoms are resolving, followed by 5 days of wearing a mask when around others.
Read More
The omicron variant multiplies about 70 times faster inside the human body than the delta variant, according to new research from Hong Kong.
Read More
The CDC says healthcare workers with COVID-19 who are asymptomatic can return to work after 7 days with a negative test, according to new agency guidance.
Read More
The FDA issued emergency authorization for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in adults age 18 and older with positive results of direct SARS-CoV-2 viral testing.
Read More
An investigational COVID-19 vaccine being developed and trialed by the Walter Reed Army Institute of Research demonstrated positive results against SARS-CoV-2 variants in a study of monkeys and in a phase 1 clinical trial in humans.
Read More
The US FDA has authorized the emergency use of Paxlovid (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients age 12 and older.
Read More
Moderna’s authorized booster (50 µg) increased Omicron neutralizing antibody levels approximately 37-fold, while a 100 µg booster increased these levels approximately 83-fold.
Read More
An investigational COVID-19 vaccine made by Novavax was found to be 90% effective at preventing COVID-19 illness.
Read More
The most likely order of symptoms that COVID-19 patients experience is different for different variants of the virus, according to a new study.
Read More
According to data, Pfizer’s COVID-19 antiviral Paxlovid reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) with no patient deaths.
Read More
Vaccines conferred protection from all COVID-19 variants but there was reduced antibody neutralization of both the Beta and Delta variants.
Read More
Most cases of suspected COVID-19 vaccine-related myocarditis in people younger than 21 are mild and resolve quickly, new research reports.
Read More